Ampio pharmaceuticals, inc. (AMPE)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Product and service revenue, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

License revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

67

58

50

50

50

50

50

50

43

0

0

-

0

-

-

-

-

Total revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating expenses
Research and development

-

-

-

-

-

-

-

-

-

10,097

8,264

8,024

7,731

10,402

13,185

15,050

15,358

14,967

13,441

15,976

18,466

22,376

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

15,312

12,622

8,614

6,370

6,348

6,829

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

-

6,648

3,641

2,655

0

0

0

Research and development - related party (Note 9)

-

-

-

-

-

-

-

-

-

323

359

395

143

143

143

143

143

143

54

84

115

113

0

0

0

-

-

-

-

-

-

-

-

-

0

0

0

0

0

General and administrative

6,609

5,954

5,353

4,364

3,936

4,355

4,742

5,099

5,423

5,255

5,123

5,565

5,787

6,536

8,099

8,190

9,293

9,055

0

0

0

-

-

0

0

-

7,465

6,607

5,602

5,826

3,902

4,596

4,436

4,504

5,336

4,669

0

0

0

Selling, general and administrative

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

21,921

18,576

13,967

10,735

10,285

11,184

13,523

14,689

16,248

15,676

13,747

13,985

13,662

17,082

21,428

23,384

24,796

24,167

0

0

0

-

-

-

30,463

24,073

20,293

17,151

12,960

11,870

12,663

12,626

11,924

11,152

9,022

7,390

0

0

0

Loss from operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income (expense)
Interest income (expense)

64

77

51

40

19

-5

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest (expense) income

-

-

-

-

-

-

-

-

-

3

6

9

16

23

18

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest (expense) income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

8

18

22

0

0

0

Unrealized loss on fair value of debt instruments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-5,585

0

0

0

-

-

Derivative gain

8,860

4,869

2,953

12,753

16,523

45,298

2,799

-6,092

-11,731

-36,218

1,893

2,324

211

-915

-715

0

0

-

0

-

-

-

-

-

-

-516

-444

16

-77

205

494

560

-450

-1,555

0

0

0

-

-

Unrealized loss on trading security

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized loss on trading security

-

-

-

-

-

-

-

-

-

-

-

-

-176

-146

64

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

0

0

-

15

22

22

21

17

11

10

6

4

2

0

0

0

Loss from equity investment in Aytu BioScience, Inc.

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,043

-1,043

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total other income (expense)

8,924

4,946

2,882

12,670

16,419

45,170

0

0

0

-

1,627

2,125

-640

-2,081

-1,670

-1,023

-326

59

182

188

183

142

20

-235

-378

-504

-428

38

-55

227

512

572

-439

-7,142

-7,517

-7,797

0

0

0

Net loss from continuing operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-24,107

0

0

0

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss from discontinued operations (Note 4)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-9,606

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-33,713

-33,035

-34,949

-36,168

-39,048

-36,756

-33,336

-30,821

-24,528

-19,252

-15,676

0

-

0

0

-

-

-

-

-

-

-

Net loss applicable to non-controlling interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,703

-1,328

-1,118

-1,001

-923

-875

-785

-719

-519

0

0

0

-

-

-

-

-

-

-

-

-

-

Net loss, before income tax

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-12,101

-12,010

-12,333

-18,276

-16,534

0

0

0

-

Foreign tax expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Net (loss) income

-12,997

-13,630

-11,085

1,935

6,134

33,986

-10,665

-20,719

-27,948

-51,891

-12,120

-11,859

-14,303

-19,163

-26,023

-29,188

-31,491

-32,010

-31,707

-33,830

-35,166

-38,125

-35,226

-32,140

-30,042

-24,008

-20,672

-17,062

-12,965

-11,593

-12,101

-12,093

-12,415

-18,359

-16,616

-15,187

0

0

0

Net (loss) income per common share: Basic

-0.03

0.00

-0.05

0.00

-0.05

-

0.06

0.05

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net (loss) income per common share: Diluted

-0.04

-0.01

-0.05

-0.03

-0.05

-

-0.02

-0.03

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Basic weighted-average common share outstanding

159,054

154,062

142,207

115,031

111,104

-

96,930

86,300

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted average number of common shares outstanding: Diluted

160,558

152,458

142,207

118,770

111,104

-

115,346

92,999

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

From continuing operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.14

-0.10

-0.11

-0.11

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

From discontinuing operations and non-controlling interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.06

-0.04

-0.03

-0.03

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Basic and diluted net (loss) income per common share

-

-

-

-

-

-

-

-

0.27

-0.66

-0.06

-0.04

-0.03

-0.06

-0.07

-0.10

-0.13

-0.20

-0.14

-0.14

-0.14

-0.18

-0.18

-0.17

-0.23

-0.19

-0.16

-0.17

-0.11

-0.10

-0.07

-0.08

-0.09

-0.03

-0.09

-0.10

-0.49

-0.14

-0.07

Weighted average number of common shares outstanding

-

-

-

-

-

-

-

-

82,943

75,093

68,232

60,623

57,240

57,217

53,842

52,016

52,016

51,998

51,998

51,989

51,981

52,068

51,969

51,917

44,950

41,907

37,106

37,090

37,072

37,069

36,477

31,260

31,126

29,065

28,679

28,284

18,025

17,107

17,069